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Abstract: Modern imaging techniques that can provide functional 
information on tumor vascularization, metabolic activity, or cellular-
ity have seen significant improvements over the past decade. However, 
most of these techniques are currently not broadly utilized neither in 
clinical trials nor in clinical routine, although there is a large agree-
ment on the fact that conventional approaches for therapy response 
assessment such as Response Evaluation Criteria in Solid Tumors or 
World Health Organization criteria—that exclusively focus on the 
change in tumor size—are of less value for response assessment in 
modern thoracic oncology. The aim of this article comprises two parts: 
a short review of the most promising state-of-the-art imaging tech-
niques that have the potential to play a larger role in thoracic oncol-
ogy within the near future followed by a meeting report including 
recommendations of an interdisciplinary expert panel that discussed 
the potential of the different techniques during the Dresden 2013 Post 
World Congress of Lung Cancer (WCLC) - International Association 
for the Study of Lung Cancer (IASLC) meeting. It is intended to pro-
vide a comprehensive summary about ongoing trends and future per-
spectives on functional imaging in thoracic oncology.
Key Words: Lung cancer, Staging, Response assessment, Diffusion 
weighted imaging, Dynamic contrast-enhanced CT, PET–CT, Dual-
energy CT, Volumetric measurements
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Lung cancer is still the leading cause of cancer-related death in both men and women in the western world, with 80 to 85% 
of cases being non–small-cell lung cancer (NSCLC).1 The past 
decade has seen significant breakthroughs in the understanding 
of the molecular biology of lung cancer. Signaling pathways 
that are vital for tumor growth have been identified and can be 
effectively targeted by novel pharmacologic agents, resulting 
in significantly improved outcome of patients with lung can-
cer.2 Parallel to the progress in lung cancer treatment, imaging 
techniques aiming at improving diagnosis, staging, response 
evaluation, and detection of recurrence have also considerably 
advanced in recent years.3 However, standard morphologic 
computed tomography (CT) and magnetic resonance imaging 
(MRI) as well as 2-[18F]-Fluoro-2-deoxy-glucose (18F-FDG) 
positron emission tomography–CT (PET–CT) are still the 
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currently most frequently utilized imaging modalities in clini-
cal practice and most clinical trials.4,5 Novel functional imaging 
techniques such as dual-energy CT (DECT), dynamic contrast-
enhanced CT (DCE-CT), diffusion-weighted MRI (DW-MRI), 
perfusion MRI, and PET–CT (with tracers that are more spe-
cific than 18F-FDG) have not yet been broadly implemented, 
neither in clinical practice nor in phase I–III clinical trials.
In this context, Nishino et al.6 recently reviewed per-
sonalized tumor response assessment in the era of molecular 
treatment in oncology. The authors concluded that the con-
cept of personalized medicine with regard to cancer treat-
ment has been well applied in therapeutic decision-making 
and patient management in clinical oncology. However, it 
was observed that the developments in imaging techniques 
for tumor response assessment had not paralleled advances 
in cancer treatment, and had not sufficiently incorporated 
state-of-the-art functional information. Functional informa-
tion on tumor response is highly required because there is 
growing evidence that the current objective criteria for treat-
ment response assessment based on structure alone may not 
reliably indicate treatment failure and do not adequately rep-
resent disease biology. Molecular-targeted therapies, immu-
nological agents as well as stereotactic radiotherapy induce 
effects that differ from those induced by classic cytotoxic 
treatment including intratumoral hemorrhage, changes in 
vascularity, and tumor cavitation and thus require new cri-
teria and/or approaches as patients may be inappropriately 
treated. Conventional approaches for therapy response 
assessment such as RECIST or WHO criteria that exclu-
sively focus on the change in tumor size are of less value for 
response assessment of targeted drugs.7,8
The motivation for the organization of this novel imag-
ing advisory board was the perception of the authors about 
the ‘translation gap’ between radiologists and pneumologists, 
thoracic oncologists, preclinical researchers, radiation oncol-
ogists, and thoracic surgeons. This ‘translation gap’ regards 
novel therapy approaches and state-of-the-art imaging tech-
niques, especially with respect to the application of functional 
imaging techniques in clinical trials. The first Advisory Board 
entitled ‘Potential Integration of Novel Imaging Techniques 
in Staging, Therapy Response Monitoring and Surveillance 
in NSCLC’ was held on December 7, 2013, in Dresden, 
Germany, one day after the ‘Post-WCLC 2013 Meeting’. The 
Advisory Board was divided in two main sessions. In the first 
educational part, invited imaging experts summarized the 
current scientific evidence on novel functional imaging tech-
niques and weighed the potential pros and cons for the inte-
gration of these techniques into future clinical trials. In the 
second discussion part, all invited multi-disciplinary experts 
discussed the value and the applicability of novel functional 
imaging techniques for various clinical scenarios.
Accordingly, this article comprises two parts: a short 
review of the relevant subject areas followed by a meeting 
report including recommendations of the expert panel. It is 
intended to provide a comprehensive summary about ongo-
ing trends and future perspectives on functional imaging. The 
advisory board should be considered as a work in progress 
meeting that is intended to be continued in 2015.
Educational Part: Imaging Techniques
Volumetric approaches for therapy monitoring
The expert committee discussed volumetric data analy-
sis and there was a broad consensus about the need for volu-
metric tumor measurements based on the available literature. 
The 7th edition of the TNM-staging system demonstrated 
the significance of the primary tumor extent on the progno-
sis of patients with NSCLC.1 Thus, three-dimensional meth-
ods to accurately assess the primary tumor extension before 
and during therapy have gained increased attention over the 
past years, because it has been demonstrated that even in CT 
studies with consistent scan parameters, minor variations in 
slice position or patient orientation considerably influence the 
results of tumor measurements.9 Moreover, inter-assessor vari-
ability might affect tumor response assessment with potential 
therapeutic consequences.9 Therefore, advanced methods for 
precise and reproducible tumor measurements over time are 
clinically needed.10
Several studies have demonstrated that tumor volume 
measurements in NSCLC have a significantly higher repro-
ducibility than measurements of maximum tumor diam-
eters.11–15 The importance of tumor volume measurements 
for the prediction of treatment outcome after chemotherapy 
and radiotherapy has also been evaluated. All of these stud-
ies reported the superiority of volumetric measurements over 
RECIST criteria.16–18 These findings are even more important 
in patients undergoing targeted therapies. Here, the limited 
ability of RECIST criteria to characterize tumor response and, 
therefore, to guide therapeutic decisions are more pronounced 
due to the differences in response patterns, such as decreasing 
tumor density, cavitation, and intra-tumor hemorrhage.4,6,19–22 
A recent study on patients with advanced NSCLC and epi-
dermal growth factor receptor (EGFR) mutations showed that 
only the tumor volume decrease at 8 weeks of EGFR-tyrosine 
kinase inhibitor (TKI) therapy was associated with longer sur-
vival.23 Based on the results of these and other studies, tumor 
volume measurements using semi-automated software tools 
could be easily and cost effectively implemented in the design 
of future clinical trials, helping to overcome RECIST limita-
tions related to targeted therapies.
Novel morphologic approaches for the assessment of 
therapy response
As mentioned above, tumor response assessment in 
patients undergoing targeted therapies requires new strategies 
beyond RECIST and WHO criteria. Thus, Lee et al.24 evalu-
ated new response criteria in patients treated with EGFR-TKIs 
compared with RECIST and proposed new criteria for a more 
accurate response assessment in patients with NSCLC undergo-
ing TKI therapy. In this study, a decrease of tumor attenuation 
in Hounsfield units was an accurate marker of therapy response 
even in tumor s with a less than 30% decrease in maximum 
size. The decrease in tumor attenuation was caused by the high 
incidence of tumor cavitation after EGFR-TKI therapy as a sur-
rogate of central tumor necrosis. This sign of therapy response 
was not observed in patients undergoing standard chemother-
apy. By applying these criteria, patients classified as respond-
ers showed a higher median overall survival (18.4 months) than 
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patients with poor response (8.5 months). In contrast, RECIST 
criteria were negative in 16 patients that achieved response 
according to the new criteria. In addition, tumor cavitation was 
used as a biomarker of therapy response in a recent phase II trial 
of neoadjuvant bevacizumab plus chemotherapy.25
Dual-energy CT
DECT, a relatively new CT technique, allows absolute 
quantification of iodinated contrast material in tumor tissues. 
The physical principle of DECT is based on the differential 
attenuation of iodinated contrast material depending on the 
tube voltage (Fig. 1).26,27 By applying two different X-ray 
spectra during a routine contrast-enhanced chest CT examina-
tion, the total amount of iodinated contrast material as a surro-
gate marker of blood volume within a tumor can be calculated 
without an additional CT examination. The main advantage of 
DECT is its easy application that causes no additional proce-
dural costs and does not require increased radiation doses or 
additional injections of iodinated contrast materials (Fig. 2). 
The DECT technique is provided by all major CT manufac-
turers and generates standard CT images that allow all con-
ventional morphological measurements, with the inherent 
advantage that the tumor blood volume can also be measured. 
Furthermore, DECT datasets can be used to calculate non-
contrast CT images from contrast enhanced CT data without 
the need of a separate unenhanced scan. Using these virtual 
noncontrast datasets, calcifications can be visualized and 
potentially differentiated from intra-tumor contrast enhance-
ment.28 Even more important, DECT could potentially help 
to differentiate between intra-tumor hemorrhage and contrast 
enhancement as for example shown in gastrointestinal stro-
mal tumors under TKI therapy.29 This information provided by 
DECT may gain more importance within the future because 
changes in tumor density caused by intra-tumor hemorrhage 
are more frequently observed during targeted therapy than 
during cytotoxic chemotherapy.30 Several studies have applied 
DECT for the differentiation between benign and malignant 
lesions, to improve tumor visualization, and to assess treat-
ment response in renal cancer, hepatic cancer, and gastrointes-
tinal stromal tumors .29,31,32 One study evaluated the usefulness 
of DECT for the characterization of pulmonary nodules.28 In 
this study, DECT-measured iodinated contrast enhancement 
correctly classified 45 of 49 nodules into benign versus malig-
nant tumors. Besides the classification of pulmonary nodules, 
DECT could potentially be applied to evaluate the therapy 
response by analyzing changes in the tumor iodine and, 
accordingly, blood volume, especially in patients undergoing 
anti-angiogenic-targeted therapies.
One study showed a strong correlation between the 
maximum standardized uptake value (SUV
max
) of 18F-FDG 
PET–CT and the tumor iodine content as calculated from 
DECT datasets.33 Another study by Kim et al.34 evaluated the 
applicability of DECT for response assessment in NSCLC 
patients treated with anti-angiogenic agents and found discor-
dant responses between RECIST- and DECT-based response 
assessment. The authors concluded that DECT is a useful tool 
for response evaluation after anti-angiogenic treatment by 
providing quantitative data on tumor enhancement and vas-
cularity without obtaining noncontrast-enhanced images.34 
Ogawa et al.35 proposed DECT iodine measurements for 
advanced assessment of mediastinal lymph node vascularity 
in patients with lung cancer. The fact that DECT can be used 
for the analysis of pulmonary perfusion represents another 
advantage. Chae et al.28 compared DECT perfusion imaging 
and lung perfusion scintigraphy for the prediction of postop-
erative lung function in patients undergoing lung resection. In 
this study, postoperative lung function was more accurately 
predicted by DECT than by perfusion scintigraphy. Beside the 
visualization and quantification of iodinated contrast material, 
the spectral DECT effect can also quantify inhaled xenon to 
assess pulmonary ventilation and therefore offers an alterna-
tive to pulmonary ventilation scintigraphy.36
In summary, DECT could be easily integrated into 
clinical trials, because the technique is widely available and 
requires only minor changes on most state of the art CT scan-
ners. DECT provides additional information on tumor blood 
volume as a surrogate for, for example, tumor response, as 
well as pulmonary perfusion and ventilation without the 
requirement of an increased radiation dose (Table 1).
Dynamic contrast-enhanced CT
Tumor angiogenesis leads to an increase of regional 
blood flow (BF) and blood volume (BV) and, thereby, con-
trast-enhancement of lung cancer tissue. Tumor perfusion 
FIGURE 1.  The figure demonstrates 
the principle of dual-energy CT. 
Dual-source CT systems are one way 
to acquire dual-energy CT datasets 
by operating the two X-ray tubes 
with two different tube voltages at 
the same time. Materials with high 
anatomic numbers like iodine show a 
different X-ray attenuation depend-
ing on the applied tube voltage 
(image on the left). The different tis-
sue attenuation at different tube volt-
ages allow to selectively visualize and 
quantify iodinated contrast material 
and thus blood within the tumor. CT, 
computed tomography.
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and therapy-induced perfusion changes can be quantified 
by DCE-CT. DCE-CT can assess tumor density at different 
times, based on consecutive CT scans that are acquired after 
the injection of contrast material (Fig. 3). The technique pro-
vides quantitative data of tumor BF, BV, permeability, and the 
mean transit time of iodinated contrast material through the 
tumor (Fig. 2).37–43
The feasibility of DCE-CT to characterize pulmo-
nary nodules has been proven in a prospective, multicenter 
trial evaluating DCE-CT for the classification of benign and 
malignant pulmonary nodules.41 Moreover, several stud-
ies have correlated the results of DCE-CT to histological 
parameters of tumor angiogenesis such as micro-vessel den-
sity (MVD) and vascular endothelial growth factor (VEGF) 
expression. Tateishi et al.44 for example analyzed the cor-
relation of tumor enhancement over time with MVD and 
VEGF expression in 130 patients with histologically proven 
NSCLC. They found a significantly higher peak enhancement 
in VEGF-positive tumors than in VEGF-negative tumors. In 
addition, peak-enhancement of VEGF-positive tumors had 
FIGURE 2.  CT images of a 68-year-old patient with a central NSCLC that underwent whole tumor volume dynamic contrast-
enhanced CT (A–D) as well as dual-energy CT for tumor staging before TKI therapy. A, One late arterial phase gray scale image 
25 seconds after the contrast agent administration. B–D, Color-coded images representing blood volume (B), blood flow (C), 
and the mean transit time (D) of the contrast agent through the tumor. E and F, The corresponding dual-energy CT images. The 
blood volume (tissue iodine content) is color coded within the image and correlates with the blood volume from the dynamic 
series (B). The arrows demonstrate a highly perfused lymph node metastasis as well as a contralateral intrapulmonary metastasis. 
CT, computed tomography; NSCLC, non–small-cell lung cancer, TKI; tyrosine kinase inhibitor.
FIGURE 3. Left figure The basic principle of dynamic contrast-enhanced CT. Subsequently after the start of the intravenous admin-
istration of iodinated contrast material the anatomic region of interest is scanned several times with a very short so called inter-scan 
delay (usually 1.5–2.5 seconds in thoracic malignancies) between the different acquisitions. The measurement of the tissue con-
trast attenuation in all different acquisitions allows calculation of time intensity curves as well as calculation of multiple quantitative 
tissue parameters including blood volume, blood flow, tissue permeability, and the contrast agent mean transit time through the 
tissue. Right figure The advantage of whole tumor dynamic contrast-enhanced CT (lower row) that is not affected by tumor motion 
during different breathing cycles as well as inhomogeneous tumor tissue. Upper row Limitations of dynamic contrast-enhanced CT 
with older CT systems that limited the clinical value of the technique. CT, computed tomography.
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a significantly positive correlation with MVD (r = 0.65). 
Moreover, lymph node-positive lung cancer patients showed a 
higher peak enhancement, VEGF expression, and MVD than 
lymph node-negative patients.
DCE-CT may be used for the assessment of tumor 
response to targeted therapy or radiotherapy. It has been 
reported that micro-vascular damage is a key mechanism in 
tumor response to radiation.45 Therefore, reduced volume of the 
vascular bed after radiation therapy is reflected by reduced BF, 
BV, and permeability. Ng et al.46 demonstrated that hypo-frac-
tionated radiotherapy increases both the tumor vascular blood 
volume and the permeability of NSCLC. Wang et al.47 dem-
onstrated that NSCLCs with higher perfusion values, as mea-
sured by DCE-CT, are more sensitive to radiochemotherapy 
than tumors with lower perfusion values. Moreover, the study 
suggests that after radiochemotherapy, DCE-CT results signifi-
cantly predict early tumor response and overall survival among 
patients with NSCLC. In another study by Lind et al.,48 tumor 
BF measured by DCE-CT in 23 patients with advanced NSCLC 
correlated with the response to anti-angiogenic and anti-EGFR-
targeted therapy, e.g., sorafenib and erlotinib. DCE-CT was per-
formed at baseline as well as 3 and 6 weeks after the initiation 
of treatment. Tumor perfusion was lower in responders than in 
nonresponders at week 3 and 6. Patients with a large decrease 
of BF at week 6 tended to have a longer progression-free sur-
vival. Fraioli et al.49 performed DCE-CT at day 40 and 90 after 
initiation of conventional and anti-angiogenic chemotherapy in 
patients with advanced lung adenocarcinoma. In this study, BF, 
BV, and permeability values were higher in responding patients 
than in that of the other patients, with significant differences for 
BF, BV, and permeability at second follow-up. The time to peak 
contrast enhancement was higher in nonresponding patients than 
in that of treatment responders. Despite these promising results, 
DCE-CT has not yet been established as a standard procedure in 
clinical routine as the applicability of this technique was limited 
in the past because data acquisition was restricted to single or 
few slides throughout the tumor. However, with currently avail-
able state-of-the-art CT systems, whole tumor coverage with 
an acceptable radiation dose using low tube voltage settings 
became feasible.37,46 This scanner equipment has recently been 
demonstrated to achieve a substantial intra-observer agreement 
for lung cancer DCE-CT measurements, encouraging its use 
for tumor characterization and therapy response monitoring.50 
Moreover, whole tumor DCE-CT may allow advanced sub-
classification of different lung cancer entities.51 Thus, DCE-CT 
seems to be an attractive and cost–effective method to monitor 
response to treatment in patients undergoing anti-angiogenic 
therapies although one has to acknowledge that based on the 
currently available evidence the technique is still not “ready for 
prime time” to replace RECIST of WHO criteria in prospective 
clinical trials (Table 1).
Positron emission tomography
18F-FDG PET–CT is the current clinical gold standard 
imaging modality for the primary staging of NSCLC and 
small-cell lung cancer and has been recommended by recent 
guidelines.52–54
In addition to primary tumor staging,18F-FDG PET–CT 
has been shown to be superior to standard CT and MRI for 
the detection of recurrent disease after surgery, local ablative 
therapies such as microwave ablation and chemotherapy.55–64 
According to the Positron Emission Tomography Response 
Criteria in Solid Tumors (PERCIST) guidelines, a reduc-
tion in 18F-FDG PET uptake of 30% is defined as a metabolic 
response, whereas an increase of 30% is defined as progres-
sion.65 Moreover,18F-FDG PET–CT defines more precisely the 
target volumes for both, conventional as well as stereotactic 
radiotherapy planning.66–68
The pyrimidine analog 3′-deoxy-3′-[18F]-
fluorothymidine (18F-FLT) is phosphorylated by thymidine 
kinase 1 into 18F-FLT monophosphate after cellular uptake, 
leading to intracellular sequestration of radioactivity.69 
Because thymidine kinase 1 is a principal enzyme in the 
salvage pathway of DNA synthesis, 18F-FLT PET reflects 
cellular proliferation. According to several studies, 18F-FLT 
PET can be used to monitor the response to TKI therapies 
in patients with NSCLC.69 A phase II trial by Zander et al.70 
demonstrated that an early 18F-FLT PET response 1 week 
after the initiation of treatment predicted significantly longer 
PFS. Moreover, Kahraman et al.71 showed that metabolically 
active volume measurement in early 18F-FLT PET may have 
an additional predictive value for the response of patients 
with advanced NSCLC treated with erlotinib. Based on the 
currently available literature, 18F-FLT PET is a promising 
measure for assessing the response to targeted therapy in 
patients who have a higher likelihood of EGFR mutations in 
their tumors. Thus, the role of 18F-FLT PET will likely gain 
more importance in nonsmoking Asian patients with adeno-
carcinoma as well as other patient cohorts that are more prone 
to EGFR mutations.72
[68Ga]-DOTA-Tyr3-octreotate (68Ga-DOTA-TATE) PET 
has shown superiority when compared with 18F-FDG PET for 
the staging and response evaluation of pulmonary neuroendo-
crine tumors (Table 1).73
Magnetic resonance imaging
Multi-parametric MRI is already well established and 
recommended as the gold standard imaging modality for the 
assessment of brain metastasis.74 Moreover, MRI has the best 
diagnostic capabilities to visualize the mediastinal and chest 
wall infiltration due to both its inherent high soft tissue con-
trast and its ability to acquire dynamic cine-MRI sequences 
that allow to visualize tumor movement during several heart 
beats or breathing cycles. Another indication for MRI that is 
already widely employed is the assessment of bone metas-
tasis. Several studies as well as meta-analysis have demon-
strated that MRI is of equal or only slightly less diagnostic 
accuracy when compared with both 18F-FDG PET–CT and 
bone scintigraphy.75–77
Beyond those indications, experimental studies in 
recent years have mainly focused on DW-MRI as a tool for 
accurate staging of mediastinal lymph nodes and the evalua-
tion of tumor response during therapy. DW-MRI visualizes the 
microscopic movement of water molecules within tissues and 
has been proposed for the differentiation between benign and 
malignant lymph nodes. In metastatic lymph nodes, diffusion 
is limited due to the obstruction of lymph nodes by tumor cells 
(Fig. 4). Therefore, metastatic lymph nodes have significantly 
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lower apparent diffusion coefficient (ADC) values than that of 
the benign lymph nodes.78
Although the role of MRI, especially DW-MRI, for 
lymph node staging of NSCLC has not been as well studied as 
that of 18F-FDG PET–CT, recent studies indicate that MRI and 
18F-FDG PET–CT may provide comparable diagnostic infor-
mation.79–83 In a study by Wu et al.,79 DW-MRI provided even 
more specificity in preoperative mediastinal lymph node stag-
ing when compared with 18F-FDG PET–CT, with no significant 
difference in sensitivity. Hasegawa et al.84 used DW-MRI in 42 
patients with NSCLC before surgical resection. In this study, 
DW-MRI detected 80% of all histopathologically proven metas-
tases and accurately identified 97% of patients without medias-
tinal lymph node metastasis. Nomori et al.85 directly compared 
the accuracy of DWI-MRI and 18F-FDG PET–CT for deter-
mining N category in patients with NSCLC and compared the 
results of both modalities to those of histopathological exami-
nation. Among 734 analyzed lymph node stations, histopathol-
ogy revealed 36 metastatic and 698 nonmetastatic lymph nodes. 
There was no significant difference between DW-MRI and 18F-
FDG PET–CT in the detection of metastatic lymph node sta-
tions. However, DW-MRI was more accurate than 18F-FDG 
PET–CT in the identification of nonmetastatic lymph node sta-
tions because of the lower rate of false-positive results.
A study by Ohno et al.86 compared the predictive val-
ues of DWI-MRI and 18F-FDG PET–CT for tumor response 
to therapy and survival in patients with NSCLC undergoing 
combined chemoradiation therapy. A total of 64 patients with 
stage III NSCLC underwent pretherapeutic DW-MRI and 18F-
FDG PET–CT. For the quantitative prediction, the ADC val-
ues for DW-MRI and the SUV
max
 for PET/CT were measured 
and compared. In this study, DW-MRI showed significantly 
better specificity and accuracy for the prediction of response 
and survival when compared with 18F-FDG PET–CT.86
23Na MRI is a very new imaging technique that allows 
the visualization of tissue 23Na concentrations. It might 
therefore represent a valuable functional biomarker for tis-
sue viability during and after therapy. Proliferating malignant 
cells have an abnormally high 23Na content, because the nor-
mal intracellular 23Na concentration of approximately 10 to 
15 mmol/liter is elevated as a result of altered Na+/H+ trans-
port kinetics and pH.87 Moreover, angiogenesis and increased 
interstitial space also lead to increased 23Na tissue concentra-
tion in tumors. Although 23Na-MRI has been described more 
than 20 years ago, it was technically limited to experimen-
tal animal studies or neurological applications in humans.88 
However, technical developments in MRI and the commercial 
availability of 23Na-tuned coil systems have now extended the 
clinical application.89–94 So far, only one study has evaluated 
the feasibility of 23Na-MRI in patients with NSCLC. It con-
cluded that 23Na-MRI could provide valuable clinical informa-
tion about tumor viability.95 However, the technique has not 
been systematically evaluated in clinical studies with respect 
to staging accuracy, response assessment, and prediction of 
patient outcome (Table 1).
PET–MRI
PET–MRI has been introduced and employed in a few 
institutions over the past 5 years worldwide. The potential 
advantage of PET-MRI is best described by the combina-
tion of metabolic/functional PET information, high soft tis-
sue contrast of MRI, and functional information provided 
by DW-MRI. However, MRI has some inherent limitations 
in lung imaging. One limitation is the low proton density, 
which is responsible for the low signal-to-noise ratio of lung 
parenchyma. Another limitation results from the multiple 
air–tissue interfaces with large magnetic field gradients, 
causing susceptibility artifacts and inter-voxel phase disper-
sion of spins that lead to a very low T2* relaxation time of 
the lung parenchyma. The currently available literature is 
insufficient to establish a clear role for the clinical role of 
PET–MRI for lung cancer imaging. One study systemati-
cally compared 18F-FDG PET–CT and 18F-FDG PET–MRI 
in 22 patients with confirmed NSCLC for primary and loco-
regional lymph node staging using histopathology as refer-
ence standard.96 In this study, 18F-FDG PET–CT compared 
equal to 18F-FDG PET–MRI. Thus, the authors concluded 
that 18F-FDG PET–MRI does not provide advantages in 
thoracic staging of NSCLC patients.96 Another study that 
compared 18F-FDG PET–CT and 18F-FDG PET–MRI in 
227 patients with different tumors including NSCLC, head 
and neck and colon carcinoma did not find statistically 
significant superiority of 18F-FDG PET–MRI to 18F-FDG 
PET–CT.97
In summary, no studies have clearly described supe-
riority of 18F-FDG PET–MRI over 18F-FDG PET–CT for 
lung cancer staging and assessment of treatment response. 
However, future studies are required to investigate whether 
a combination of metabolic PET information and DW-MRI-
measured ADC values could improve diagnostic accuracy of 
mediastinal lymph node staging. Such combination has been 
described as successful by one study that did not use a hybrid 
PET–MRI system (Table 1).98
FIGURE 4.  The figure demonstrates the principle of DWI 
with magnetic resonance imaging. Water molecules show a 
random Brownian movement in normal tissue leading to low 
signal intensity on DWI images. In cancer tissue with more 
cellularity and/or cellular edema, the Brownian movement is 
restricted which can be visualized on DWI images and quanti-
fied using the ADC. DWI, diffusion-weighted imaging; ADC, 
apparent diffusion coefficient.
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SUMMARY OF DISCUSSION: 
RECOMMENDATIONS
GENERAL COMMENTS
After the summary of novel imaging techniques, it 
became clear that there is a need for interdisciplinary inter-
action on imaging, as there is a lack of knowledge among 
radiologists about clinically useful measures and required 
radiology research, as well as among clinicians about ongoing 
developments and opportunities in imaging. All participants 
agreed that the communication between radiologists and cli-
nicians needs further improvement in quantity and quality. 
Moreover, the communication between radiologists and clini-
cians on ongoing developments and their potential applica-
tions in clinical trials should be formalized and accelerated. 
There was also a general consensus about the need for more 
and earlier integration of lung cancer radiology specialists into 
the planning of clinical trials. This should ensure that the most 
TABLE 1.  Strengths, Potential Indications and Limitations of the Discussed Imaging Techniques at a Glance
Imaging Technique Strengths and Indications Limitations
Dynamic  
contrast-enhanced CT
•   Absolute quantification of tumor perfusion parameters possible:
°  Blood flow
°  Blood volume
°  Mean transit time
°  Tumor permeability
•   Relative in inexpensive imaging technique as it can be included 
into a regular staging CT and only requires approximately 15 
minutes more scanner room time
•   Robust imaging technique that generates comparable results 
between different scanners from different vendors if protocols are 
adapted
•   Reproducible for follow-up examinations.
•   Potential best indications:
°  Patients undergoing anti-angiogenic therapy
•   High spatial resolution
•   Requires state of-the-art CT systems that allow whole 
umor coverage to compensate for:
°  Tumor motion between the different acquisitions
°  Inhomogeneous tumor tissue if only a small part of the 
tumor is covered as it was with previous CT system 
generations the reproducibility to image identical areas 
of a tumor during follow-up examinations is almost 
impossible
•   Additional radiation dose to the patient requires 
appropriate indication after the risk has been weigh up 
against the benefit of the additional information provided 
by the additional examination
•   Additional amount of contrast material (usually between 
40 and 60 cc)
•   Requires special training for radiologists and technicians
Dual-energy CT •   Imaging of tumor vascularization
•   Provides standard CT images that allow all standard 
measurements (e.g., RECIST, WHO, mWHO etc.) while at the 
same time quantitative information about the tumor blood volume 
can be calculated
•   No additional radiation dose, contrast material and CT room time 
→ Potential technique for all patients
•   Easy implementation in clinical routine with no additional costs
•   Assessment of tumor blood volume during therapy
•   Correlates with 18F-FDG tumor uptake
Potential better differentiation between tumor and atelectasis
•   Requires state of-the-art CT systems that provide  
dual-energy CT
•   Low current evidence level requires more implementation 
into clinical trials
Diffusion-weighted MRI •   Imaging of tumor cellularity
•   Good correlation with 18F-FDG PET–CT for mediastinal 
lymph node assessment with studies indicating potential higher 
specificity
•   High accuracy for bone metastasis similar to scintigraphy and 
18F-FDG PET–CT
•   Easy integration into standard MRI examination protocols without 
relevant additional costs (slightly longer examination time)
•   Provides functional and quantitative information about tumor 
cellularity
•   High potential for patients undergoing targeted therapies 
especially TKI therapies because the technique quantifies tissue 
cellularity
•   No standardization between different vendors
•   Values are influenced by differences in MRI scanner 
field strengths and the applied sequences. Need for 
standardized DWI-MRI examination protocols
•   Not applicable for patients with MRI contraindications 
(Pacemaker etc.).
•   Vulnerable to image artifacts
•   Low current evidence level for the value of therapy 
monitoring
Sodium (23Na) MRI •   Visualization and quantification of tissue sodium concentration
•   Malignant tumors show higher tissue sodium concentrations
•   High potential for very early response assessment in patients 
undergoing targeted therapies since changes in the Na+/K+ATP- 
ase pump and thus the tissue sodium concentration appear before 
definite cell death
•   Research technique with poor evidence in lung cancer 
imaging
•   Long examination times
•   Poor spatial resolution
•   No broad availability
•   Not applicable for patients with MRI contraindications 
(Pacemaker etc.)
3′-deoxy-3′-[18F]- 
fluorothymidine PET
•   Specific marker for cellular proliferation
•   Biomarker for early response assessment
•   Already good evidence provided by high quality clinical studies
•   Potential best indication in patients undergoing TKI therapies in 
which early response assessment is important
•   Expensive additional procedure with limited availability
•   No standardized protocols and standardized uptake value 
reference values
CT, computed tomography; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization; mWHO, modified World Health Organization criteria; 
FDG, fluoro-2-deoxy-glucose; PET, positron emission tomography; TKI, tyrosine kinase inhibitor; MRI, magnetic resonance imaging.
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appropriate imaging methods are applied and further vali-
dated in future clinical trials investigating targeted therapies.
Overall, it was considered essential that in the era of 
molecular oncology the radiology community should get 
more actively involved in clinical trials and patient care.
Dual-Energy CT
Although DECT is now broadly available and comes 
with no additional cost or increased radiation doses, the knowl-
edge and awareness about this technology among lung cancer 
specialists is still limited. In the educational part of this article, 
available data and potential applications are described. Points 
of discussion included the characterization of pulmonary nod-
ules, which might be an important application for DECT in the 
context of lung cancer screening algorithms that would poten-
tially reduce the number of follow-up examinations in patients 
with positive findings. However, it has to be considered that 
CT examinations for lung cancer screening are generally per-
formed with low dose noncontrast-enhanced CT. Thus, DECT 
could only help to further characterize nodules that have been 
detected in those low dose noncontrast-enhanced CT examina-
tions. The correlation between DECT and PET glucose uptake 
in a single center trial is encouraging and warrants further 
investigation. It was stated that DECT might be helpful for 
early response evaluation in targeted therapies, because stan-
dard RECIST criteria are obviously insufficient in this setting.
Recommendations
It was agreed in the discussion that whenever possible 
DECT should be implemented as a standard method in clini-
cal trials to provide more evidence for its role in the future, 
particularly as advanced response parameter. In screening pro-
grams, DECT could be a valuable tool to better differentiate 
between benign and malignant lesions. It is recommended that 
data of large patient numbers should be collected.
Thus, more centers should prospectively collect stan-
dardized DECT data to generate more evidence on this prom-
ising imaging modality. DECT data could also be potentially 
useful for inclusion into upcoming TNM editions.
Whole Body MRI
The advantages or differences of MRI compared with 
CT are well known. MRI should be seen as a complementary 
imaging tool for specific questions where the higher soft tissue 
resolution of MRI is relevant (mediastinal and chest wall infil-
tration is of clinical importance). However, it was acknowl-
edged that the quality of MRI as well as the duration of the 
procedure has improved over the past years. Thus, the question 
is whether the fields of MRI application could be enlarged to 
an application in the staging algorithm of lung cancer patients. 
This would be particularly relevant for the unsolved problem 
of noninvasive mediastinal lymph node staging. Today, whole 
body MRI scans can be obtained within 40 minutes, but very 
little evidence exists about the role of whole body MRI in the 
context of lung cancer staging. It was discussed that brain, 
bone, and T4 tumors invading the mediastinum and chest 
walls are potential indications for MRI. However, the additive 
benefit to 18F-FDG PET–CT needs further evaluation.
Recommendations
It was agreed that stage III lung cancer patients would 
be the most interesting target group to investigate the signifi-
cance of whole body MRI. This group of patients represents 
almost one-third of newly diagnosed lung cancers but is very 
heterogeneous in terms of staging, treatment, and prognosis. 
Exact assessment of the local disease and exclusion of distant 
disease is crucial to guide treatment in these patients. It is rec-
ommended to determine to what extent whole body MRI, in 
comparison and in addition to 18F-FDG PET–CT, will influ-
ence treatment decisions, especially in stage III lung cancer 
in which the high rate of brain metastasis especially requires 
MRI due to the superiority for the detection of brain metasta-
sis compared with 18F-FDG PET–CT. Likewise, the possible 
combination of MRI and PET in combined PET/MRI systems 
opens new opportunities and merits further investigation.
PET–MRI
Among the topics discussed were current limitations in 
terms of worldwide availability and, therefore, impact as well 
as existing reimbursement issues. Nonetheless, this method 
might be a powerful tool warranting further evaluation due to 
its great potential in differentiating soft tissues and due to the 
improvement of mediastinal lymph node staging by a PET and 
DW-MRI combination. This is of special interest in T4 tumors, 
where invasion of surrounding structures is very difficult to 
be sufficiently clarified. In particular, the reassessment of T4 
tumors after neoadjuvant therapy to redefine operability in 
specialist units is an unmet need where PET–MRI might help. 
Likewise, staging of mediastinal lymph nodes needs to be 
improved, and PET–MRI could especially increase specificity.
Recommendations
As a first step, PET–MRI should be investigated in 
clinical trials on stage III lung cancer patients. PET–MRI 
should be used for the evaluation of the mediastinum and T4 
tumors and should be compared with PET–CT with respect to 
a potentially improved mediastinal lymph node staging (either 
with dedicated hybrid PET–MRI systems or with fused image 
datasets).
New PET Tracers
In addition to 18F-FDG PET–CT, which is now an inte-
gral part of the diagnostic algorithm in lung cancer, there are 
other promising radionuclides that have hardly been investi-
gated in clinical trials so far. Unmet needs identified during the 
discussion were the diagnosis of neuroendocrine tumors, early 
response prediction for targeted therapies (e.g., EGFR-TKIs), 
and the evaluation of patients after stereotactic radiotherapy, 
because 18F-FDG PET is not sufficient to distinguish between 
inflammation and vital tumor tissue. However, the low number 
of GCP-conform radiopharmacies limits the development and 
evaluation of new tracers for the molecular characterization of 
tumors in vivo.
Recommendations
68Ga-DOTA-TATE PET should be used as an addi-
tional imaging modality in neuroendocrine tumors. 18F-FLT 
is an example for a marker of cell proliferation that merits 
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further exploration as an early response predictor in patients 
undergoing targeted therapy. Leading centers should consider 
budgeting for on-site radiopharmacies to develop companion 
diagnostic tools for the guidance of targeted therapy. Response 
to neoadjuvant therapy should be used as a ‘window of oppor-
tunity’ for further research of functional tracer development to 
correlate tracer uptake with resected tumor tissue.
Specific Issues—Immunotherapy
Data are not sufficient to recommend any specific 
functional imaging modality for special use in patients that 
undergo immunotherapy and current technology lacks to dif-
ferentiate accurately between pseudoprogression and progres-
sion. 18F-FDG PET may be limited by the problem of chronic 
inflammation induced by immunomodulatory therapy.
Recommendation
Data about initial experiences with different modali-
ties should be collected to generate hypotheses to be subse-
quently tested in clinical trials. There was consensus that the 
theoretically most promising techniques within the context 
of response assessment in patients undergoing immunother-
apy are DCE-CT and DECT. These ‘markers’ could detect 
changes in tumor vascularity, especially if pseudoprogression 
is suspected. 18F-FLT PET–CT is a marker of cell prolifera-
tion. There was a consensus that molecular imaging modali-
ties have to be developed for targeted therapies.
Specific Issues–Follow-up after 
Ablative Therapies
Initially increased density of lung parenchyma, cavita-
tion, and fibrotic changes are observed after thermoablation 
and stereotactic body radiation therapy (SBRT). There is no 
knowledge on how to follow up these patients. Preliminary 
data suggest DCE-CT and 18F-FDG PET–CT as useful imag-
ing modalities for follow-up analyses of patients that have 
undergone SBRT or thermo-ablation. However, 18F-FDG 
PET–CT was not considered as useful within the first 12 
months after thermo-ablation and SBRT due to a false-posi-
tive inflammatory/postprocedural tracer uptake.
Recommendations
There was broad consensus about the requirement of 
studies that systematically evaluate response assessment and 
observation of recurrence after thermoablation and SBRT. 
Functional imaging techniques should be integrated prospec-
tively within clinical trials on patients undergoing SBRT and 
thermoablation. In this context, DECT, DCE-CT as well as 
DW-MRI are the most promising functional imaging tech-
niques and should be prospectively studied.
Specific Issues–3D Reconstruction
As another important issue, the discussion identified the 
clinical need for a preoperative and standardized 3D recon-
struction of thoracic vascular and trachea bronchiolar struc-
tures before video-assisted thoracoscopic surgery. However, 
it was pointed out that most centers do not provide standard-
ized 3D reconstructions although the usefulness has been 
demonstrated in clinical studies.99–101 Thus, standardized 3D 
multi-planar reformations would be of great value for sur-
geons to improve the planning of the procedure.
Recommendations
3D reconstruction can also be retrospectively done 
with any obtained CT image data derived from slices of 0.6 
to 1.5 mm, without the need for CT raw data storage. Thus, 
the communication between surgeons and radiologists and 
the training of radiologists on the requirements and expecta-
tions of thoracic surgeons need to be enhanced. Regularly per-
formed interdisciplinary workshops could help to overcome 
these obstacles.
Specific Issues–Standardized 
Radiological Reporting
The level of satisfaction with standard reports of local 
radiologists was intensively discussed. It was agreed that 
radiological reports should be more standardized and struc-
tured to include as much information as possible. The TNM 
stage should not be solely based on radiological imaging but 
on comprehensive clinical evaluations. Thus, radiology reports 
should include all descriptive and quantitative data obtainable 
from images that can help to generate the best possible clini-
cal TNM staging. There was a general perception that many 
radiology reports do not describe suspected lymph nodes by 
using published, internationally agreed lymph node maps that 
would be additionally important for accurate TNM staging.102 
It is important to emphasize that the IASLC International 
Lymph Node Map and the accompanying table of anatomi-
cal boundaries is the recognized means of describing regional 
node involvement in lung cancer by the Union International 
for Cancer Control and American Joint Committee on Cancer.
Recommendations
Standardized reporting required for accurate TNM stag-
ing should include size, chest wall, and mediastinal contact. An 
interdisciplinary board should develop standardized reports for 
lung cancer staging and follow-up. Such reports are already in 
use in, for example, breast and prostate cancer imaging.
Radiology reports should describe all information that 
can help to improve accurate clinical TNM staging.
Lymph nodes should be described according to the 
IASLC lymph node map and table of definitions.
Volumetric Tumor Measurements/Novel 
Morphological Signs for Therapy Response
No agreement was achieved on how to standardize inter-
pretation of tumor cavitation in patients that do not undergo 
dedicated targeted therapy. However, there was a consensus 
that cavitation should be considered as a sign of therapy 
response in patients that undergo targeted therapy, although 
there is no knowledge on how this finding can be integrated in 
ongoing studies that simply use RECIST criteria.
Volumetric measurement methods to follow-up indeter-
minate nodules and tumor therapy were discussed. There was 
a broad consensus that current data strongly support the use of 
volumetric tumor measurements and that these measurements 
are superior to uni- or bi-dimensional measurements.
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Recommendations
Volumetric measurements should be included within 
future studies (prospectively collected data on volumetric 
tumor size). Follow-up of indeterminate solitary pulmonary 
nodules should be performed using volumetric measurements.
Prospective trials are needed to investigate the clinical 
value of tumor cavitation during therapy, to provide more evi-
dence on this phenomenon, and to provide recommendations 
on how to integrate cavitation and decreasing tumor density 
into RECIST or WHO criteria.
Specific Issues–SUV Variance between 
Different Manufacturers
It was highlighted that measured SUV for PET imag-
ing largely differ between manufacturers. This significantly 
limits the value of PET in multicenter/multivendor studies. It 
was also pointed out that there is no agreement which SUV 
should be measured or used in clinical studies (SUV
max
 versus 
SUV
mean
). Therefore, the group concordantly emphasized the 
need for a higher level of standardization in clinical studies to 
generate manufacturer-independent thresholds for PET imag-
ing. It was mentioned in the discussion that SUV could be 
systematically recorded to potentially include those values in 
upcoming TNM editions.
Recommendations
The industry should be encouraged intensify efforts to 
standardize SUV measurement between different PET sys-
tems. However, imaging centers are also in charge to work on 
higher standardized scanning and measurement techniques.
Specific Issues—Mesothelioma
For the accurate staging of mesothelioma, there is a lack 
of evidence for all imaging modalities. Moreover, assessment of 
therapy response is still insufficient and not globally standard-
ized. There was a consensus that specific volumetric software 
applications are specifically useful for the challenging staging 
and response assessment in patients with mesothelioma.
Recommendations
18F-FDG PET–CT and DECT combine metabolic infor-
mation and high soft tissue resolution as well as information 
on total tumor blood volume that can be used for volumetric 
measurement. Further research on these modalities is there-
fore required.
Specific Issues—Thymic Tumors
The correct staging of thymic tumors is an unsolved 
problem. Because the tumor is localized in the mediasti-
num, 18F-PET–MRI would be an interesting tool. However, 
thymic tumors are rare, and 18F-PET–MRI is expensive and 
not broadly available. DW-MRI, on the other hand, is broadly 
available and has no additional cost.
Recommendations
In thymic tumors, DW-MRI should be evaluated as add 
on to standard imaging techniques to acquire additional data 
to better establish the value of the technique and to create 
stronger evidence for this rare tumor entity. Moreover, due 
to the worldwide relative small number of thymic tumors the 
set-up of a dedicated imaging database that includes DW-MRI 
should be discussed.
CONCLUSION
In summary, the discussion during this first interdisci-
plinary imaging advisory board came to the conclusion that 
a more intense and regular communication among radiolo-
gists, nuclear medicine specialists, pneumologists, thoracic 
oncologists, preclinical researchers, radiation oncologists, 
and thoracic surgeons on novel imaging techniques and their 
potential value for thoracic oncology is highly required. 
Moreover, although several of the described functional imag-
ing techniques are not yet “ready for prime time” to replace 
traditional imaging techniques, a more frequent integration 
of the techniques into prospective clinical trials could help 
to generate stronger evidence about the right use of these 
promising techniques. This allows advanced functional and 
molecular imaging being part of precision medicine in tho-
racic oncology.
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